Vaccination is among the measures implemented by authorities to control the spread of the COVID-19 pandemic. However, real-world evidence of population-level effects of vaccination campaigns against COVID-19 are required to confirm that positive results from clinical trials translate into positive public health outcomes. Since the age group 80 + years is most at risk for severe COVID-19 disease progression, this group was prioritized during vaccine rollout in Germany. Based on comprehensive vaccination data from the German federal state of Rhineland-Palatinate for calendar week 1–20 in the year 2021, we calculated sex- and age-specific vaccination coverage. Furthermore, we calculated the proportion of weekly COVID-19 fatalities and reported SARS-CoV-2 infections formed by each age group. Vaccination coverage in the age group 80 + years increased to a level of 80% (men) and 75% (women). Increasing vaccination coverage coincided with a reduction in the age group’s proportion of COVID-19 fatalities. In multivariable logistic regression, vaccination coverage was associated both with a reduction in an age-group’s proportion of COVID-19 fatalities [odds ratio (OR) per 5 percentage points = 0.89, 95% confidence interval (CI) = 0.82–0.96, p = 0.0013] and of reported SARS-CoV-2 infections (OR per 5 percentage points = 0.82, 95% CI 0.76–0.88, p < 0.0001). The results are consistent with a protective effect afforded by the vaccination campaign against severe COVID-19 disease in the oldest age group.
The German Cancer Society (DKG) offers certification of oncological centres since 2003. Meanwhile more than 260 and more than 120 certified centres for breast and prostate cancer, respectively, exist in Germany. Aim of the herein performed investigation was the identification of factors that stimulate treatment of patients with breast or prostate cancer in a certified centre. This study was based on information available in the database of the Cancer Registry of Rhineland-Palatinate, Germany. The impact of age, region of residence, tumor status, grading and presence of metastasis on patient’s decision with respect to a certain medical facility was analyzed by adjusted logistic regression. This investigation included data of 13,020 breast cancer and 10,904 prostate cancer patients diagnosed in the years 2016 to 2020. Overall, 59 % and 28 % of breast and prostate cancer patients, respectively, were treated in a DKG-certified centre. The analyses showed that residence in an urban region was associated with treatment in a certified centre (breast: OR 0.42, 95% CI (0.37-0.48); prostate: OR 0.46 95% CI (0.40-0.53)). In addition, older breast cancer patients were more often treated in hospitals without certificate (OR 1.13, 95% CI (1.04-1.24). Prostate cancer showed no association with age but early tumor stage (T1) were more often treated in hospitals without certificate (OR 1.23, 95% CI (1.03-1.46). In contrast, patients with more advanced tumors, T2 and T3, were likely to be reported by DKG-certified centres (OR 0.58, 95% CI (0.41-0.81) and OR 0.67, 95% CI (0.47-0.96), respectively). Most breast and more than a quarter of prostate cancer patients were treated in DKG-certified centres. The region of residence seemed to affect the decision for a certain facility for all patients. Whereas age at diagnosis and tumor status played a role for breast and prostate cancer patients, respectively.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.